ºÚÁϳԹÏÍø

11.04.2024

ºÚÁϳԹÏÍø presented preclinical data from our PMS2 program at the AACR Annual Meeting, San Diego, 5 - 10 April 2024.

The ºÚÁϳԹÏÍø team attended the in San Diego, 5 - 10 April 2024.

In collaboration with The University of Turin, ºÚÁϳԹÏÍø presented preclinical data from our PMS2 program.

The poster presentation 'Pharmacological inhibition of PMS2 increases tumor mutational burden, induces microsatellite instability and elicits immune mediated rejection in vivo' took place on Tuesday 9th April during Session PO.ET06.05 - Novel Therapeutics and Preclinical Models .

To download the poster (only available from 15th April 2024) please submit the form below or request a copy via this email address.

ºÚÁϳԹÏÍø AACR Annual Meeting 2024 Poster

More news

16.12.2024

Neophore appoints Michael Shih as Chief Executive Officer

ºÚÁϳԹÏÍø appoints Michael Shih as Chief Executive Officer • Highly experienced corporate development leader with a track record of international p…

22.05.2024

ºÚÁϳԹÏÍø closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb

ºÚÁϳԹÏÍø closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb Additional funding will be used to explore…

01.02.2024

ºÚÁϳԹÏÍø raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline

ºÚÁϳԹÏÍø raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline • Italian investors, NE…

Contact us at info@neophore.com  |  
Call us +44 (0) 330 128 9990